All In Biotech

Free tool

FAERS Monitor: Voltaren Arthritis Pain

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 022122 or its brand name (Voltaren Arthritis Pain, Diclofenac Sodium). Reports on generic versions are filed under their own applications.

Reports

101,833

Serious

50,966

50% of reports

Hospitalization

24,333

Death reported

9,959

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective23,949
  • product use in unapproved indication11,995
  • off label use10,311
  • pain10,013
  • fatigue9,014
  • product use issue8,022
  • rash7,842
  • rheumatoid arthritis7,286
  • product administered at inappropriate site7,061
  • abdominal discomfort6,878
  • arthralgia6,813
  • drug effective for unapproved indication6,788
  • alopecia6,322
  • systemic lupus erythematosus6,268
  • joint swelling6,248

Reports by year received

View as table
YearReports
20041,074
20051,133
20061,113
20071,326
20081,507
20091,550
20101,878
20112,386
20122,241
20131,114
20141,643
20153,496
20164,866
20173,849
20184,046
20193,933
202010,738
202115,424
20228,874
20239,932
20249,046
20256,972
20263,685

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,952,326 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product administered at inappropriate siteSignal7,061128.7125.0550,906
drug effective for unapproved indicationSignal6,78862.060.4313,372
systemic lupus erythematosusSignal6,26844.142.9217,644
rheumatoid arthritisSignal7,28614.113.883,395
joint swellingSignal6,24811.210.955,460
product use in unapproved indicationSignal11,99510.510.398,742
product use issueSignal8,0229.29.056,355
abdominal discomfortSignal6,8788.88.645,882
alopeciaSignal6,3226.86.730,771
drug ineffectiveSignal23,9493.83.851,851
rashSignal7,8423.83.715,970
arthralgiaSignal6,8133.43.311,730
painSignal10,0133.43.317,242
off label useSignal10,3112.42.49,116
fatigueSignal9,0142.42.47,613

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.